Bank Hapoalim BM Sells 11,250 Shares of Edwards Lifesciences Corporation $EW

Bank Hapoalim BM trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 37.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,150 shares of the medical research company’s stock after selling 11,250 shares during the quarter. Bank Hapoalim BM’s holdings in Edwards Lifesciences were worth $1,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of EW. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $28,000. True Wealth Design LLC grew its stake in shares of Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the last quarter. NewSquare Capital LLC increased its position in Edwards Lifesciences by 57.8% during the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after buying an additional 134 shares in the last quarter. Rakuten Securities Inc. raised its stake in Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in Edwards Lifesciences in the third quarter worth $30,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on EW shares. Mizuho lifted their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. BTIG Research reiterated a “buy” rating and issued a $103.00 target price (up previously from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the company from $90.00 to $97.00 in a report on Friday, January 9th. Finally, National Bankshares set a $92.00 price objective on shares of Edwards Lifesciences in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $96.45.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the sale, the vice president owned 31,870 shares of the company’s stock, valued at $2,729,984.20. This represents a 26.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 57,824 shares of company stock worth $4,863,323. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Down 0.1%

Shares of EW opened at $84.39 on Friday. The company’s fifty day moving average is $85.12 and its 200 day moving average is $80.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The stock has a market capitalization of $48.97 billion, a PE ratio of 36.38, a P/E/G ratio of 3.39 and a beta of 0.95. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company’s revenue for the quarter was up 14.7% on a year-over-year basis. During the same period last year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.